4.7 Article

Oral Vaccines Against Cholera

Journal

CLINICAL INFECTIOUS DISEASES
Volume 52, Issue 11, Pages 1343-1349

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir141

Keywords

-

Funding

  1. government of Republic of Korea
  2. government of Sweden
  3. government of Kuwait
  4. Bill and Melinda Gates Foundation [38590]
  5. Merck
  6. GlaxoSmithKline

Ask authors/readers for more resources

The current seventh pandemic of cholera, caused by serogroup O1, El Tor biotype, has now involved almost the entire developing world. The ongoing dynamic epidemiology of cholera, involving evolution of new strains, prolonged and more frequent epidemics, increased antimicrobial resistance, and awareness of the role of climate change upon the global burden has returned cholera to the forefront of global public health discussions. Improved water and sanitation should continue to be the mainstays of cholera-prevention efforts, but major improvements are a far-off goal for much of the cholera-affected developing world. The advent of safe and effective, new-generation oral vaccines against cholera has created renewed interest in the use of vaccines as a tool to control cholera.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available